4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company founded in 2018 that develops innovative DNA-based treatments for cancer and genetic disorders. Its pipeline features lead candidate FDMT-101 alongside additional programs such as FDMT-102 and FDMT-103, supported by a proprietary delivery platform. Under the leadership of CEO Dr. Michael Hauser and CFO Amanda Clarke, the company has raised over $50 million through strategic collaborations and milestone-based agreements. With several Phase I/II trials on the horizon, 4D Molecular Therapeutics is positioned as a promising emerging competitor in the biotech sphere.
Financial Statements
In thousands, USD
FY 2025
FY 2024
FY 2023
FY 2022
Total Revenues
85,209
37
20,723
3,129
Gross Profit
85,209
37
20,723
3,129
Selling, General & Administrative Expenses
49,060
46,579
36,494
32,908
Research & Development Expenses
195,696
141,299
97,096
80,253
Operating Profit
(159,547)
(187,841)
(112,867)
(110,032)
Interest and Investment Income
19,475
27,050
12,211
2,573
Non-Operating Income
(37)
(77)
(181)
(35)
Total Non-Operating Income
19,438
26,973
12,030
2,538
Income Before Provision for Income Taxes
(140,109)
(160,868)
(100,837)
(107,494)
Consolidated Net Income
(140,109)
(160,868)
(100,837)
(107,494)
Net Income Attributable to Common Shareholders
(140,109)
(160,868)
(100,837)
(107,494)
Basic EPS
-2.42
-2.98
-2.58
-3.32
Diluted EPS
-2.42
-2.98
-2.58
-3.32
Basic Weighted Average Shares Outstanding
57,930
53,944
39,130
32,351
Diluted Weighted Average Shares Outstanding
57,930
53,944
39,130
32,351
Shares Outstanding
57,608
45,794
43,075
32,627
FY 2025
FY 2024
FY 2023
FY 2022
Cash and Cash Equivalents
60,241
149,336
249,108
52,351
Short-Term Investments
342,414
275,541
39,124
161,203
Total Cash and Cash Equivalents
402,655
424,877
288,232
213,554
Other Current Assets
10,479
10,055
8,356
6,957
Total Current Assets
413,134
434,932
296,588
220,511
Net Property, Plant & Equipment
33,010
40,608
31,665
35,347
Long-Term Investments
111,379
80,583
10,954
4,908
Other Long-Term Assets
9,188
4,261
684
1,080
Total Assets
566,711
560,384
339,891
261,846
Accounts Payable
11,159
4,386
3,515
3,322
Accrued Expenses
26,874
18,869
12,014
8,870
Current Portion of Leases
5,592
5,637
3,149
2,655
Unearned Revenue
360
257
273
884
Total Current Liabilities
43,985
29,149
18,951
15,731
Leases
15,821
18,969
11,522
13,469
Other Long-Term Liabilities
1,241
1,660
1,589
1,309
Total Long-Term Liabilities
17,062
20,629
13,111
14,778
Total Liabilities
61,047
49,778
32,062
30,509
Common Stock
6
5
4
3
Additional Paid-in Capital
1,221,240
1,086,570
723,136
547,020
Accumulated Other Comprehensive Income
727
229
16
(1,196)
Retained Earnings
(716,304)
(576,195)
(415,327)
(314,490)
Total Common Shareholders' Equity
505,664
510,606
307,829
231,337
Total Shareholders' Equity
505,664
510,606
307,829
231,337
Total Liabilities and Shareholders' Equity
566,711
560,384
339,891
261,846
FY 2025
FY 2024
FY 2023
FY 2022
Net Income
(140,109)
(160,868)
(100,837)
(107,494)
Depreciation & Amortization
7,625
6,705
5,749
3,880
Share-Based Compensation Expense
22,016
26,116
19,665
17,121
Other Adjustments
(4,786)
(7,075)
(999)
1,144
Changes in Trade Receivables
—
—
—
47
Changes in Accounts Payable
6,773
871
896
(1,638)
Changes in Accrued Expenses
8,152
6,524
3,371
2,485
Changes in Unearned Revenue
(209)
69
(715)
(3,130)
Changes in Other Operating Activities
(8,544)
(6,927)
(2,922)
900
Cash from Operating Activities
(109,082)
(134,585)
(75,792)
(86,685)
Capital Expenditure
(536)
(3,786)
(2,771)
(11,536)
Purchases of Investments
(442,821)
(467,652)
(54,802)
(153,313)
Proceeds from Sale of Investments
350,384
169,001
173,290
147,799
Cash from Investing Activities
(92,973)
(302,437)
115,717
(17,050)
Issuance of Common Shares
112,960
337,250
156,832
3,553
Net Issuance / (Repurchases) of Common Shares
112,960
337,250
156,832
3,553
Other Financing Activities
—
—
—
(468)
Cash from Financing Activities
112,960
337,250
156,832
3,085
Increase / (Decrease) in Cash, Cash Equivalents and Restricted Cash